Papel da MMP-9 e do TGF-β na expressão de componentes da Matriz Extracelular por fibroblastos gengivais de camundongos normais e diabéticos com doença periodontal in vitro
Carregando...
Data
2019-08-02
Autores
Cano, Rodrigo das Neves [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
Na presença de Diabetes Mellitus, a doença periodontal (DP) pode acentuar o aparecimento de complicações e aumentar sua prevalência. O objetivo desta pesquisa foi avaliar se o Fator de Crescimento Transformador -β do tipo 1 (TGF-β1, sigla em inglês) e Metaloproteinase de matriz -9 (MMP-9, sigla em ingês) estão modulando a formação de componentes de matriz extracelular em fibroblastos gengivais (FG) de camundongos diabéticos e com DP. Os 24 animais foram separados em 4 grupos, e então foram tratados com estreptozotocina para indução de diabetes e foi realizado indução da DP através de ligadura com fio de seda. Após a eutanásia e coleta da gengiva, FG dos camundongos foram cultivados. A expressão gênica de RNAm e produção de proteína para MMP-9, TGF-β1 e colágeno tipo 1 (Col1a1) foram avaliadas. Eles também foram tratados com inibidores de MMP-9 e TGF-β1, e dexametasona (Dexa) por 24h. FG de animais normais e diabéticos com DP induzida tiveram expressão aumentada de MMP-9 e TGF-β1 em 6 e 24h, diminuindo em 48h. Expressão gênica de Col1a1 foi diminuída em FG com DP em 6, 24 e 48h. Inibidor de MMP-9 (MMP-9i) bloqueou a expressão gênica de MMP-9 e de TGF-β1 em FG normais e diabéticos em 24h. A expressão de col1a1 foi inibida pelo MMP-9i somente em FG normais, mas não em diabéticos. A expressão de receptor de TGF-β do tipo 1 (TGF-β R1) foi aumentada em FG normais e diabéticos, porém MMP-9i diminuiu esta expressão somente em FG diabéticos. Inibidor de TGF-β (SB431542) e Dexa interromperam a expressão gênica de MMP-9, TGF-β1 e col1a1 em FG normais e diabéticos com DP em 24h. TGF-β R1 também foi inibido em FG normais e diabéticos com DP em 24h de tratamento com SB431542. Juntos, esses achados sugerem que indivíduos diabéticos têm síntese aumentada de TGF-β e MMP-9 em FG durante a DP devido a ativação do TGF-β R1 via ALK5 e presença de MMP-9. Por outro lado, o aumento na expressão de colágeno é devido a ativação de TGF-β R1 em FG normais e diabéticos, e presença de MMP-9 em FG normais, somente.
In presence of Diabetes Mellitus, periodontal disease (PD) can accentuate complication appearance and increase prevalence. The aim of this study was to evaluate whether Transforming Growth factor-β 1 (TGF-β1) and Matrix Metaloproteinase-9 (MMP-9) are modulating the extracellular matrix components in gingival fibroblasts (GF) from diabetic mice (D) with PD. 24 animals were divided in 4 groups then they were treated with streptozotocin to diabetes induction and DP was inducted through a ligature with silk thread. After euthanasia and gingiva harvest, mice GF were cultured. MMP-9, TGF- β1, and type 1 Collagen (col1a1) mRNA expression and protein production were evaluated. They were also treated with MMP-9 and TGF-β inhibitors, and dexamethasone (Dexa) for 24h. Normal and diabetic GF from PD-induced mice had increased MMP-9 and TGF-β1 expression at 6 and 24 h decreasing at 48 h. Col1a1 gene expression was decreased in normal GF with PD at 6, 24 and 48 h. In diabetic GF col1a1 expression was inhibited at 6, 24 and 48 h. MMP-9 inhibitor (MMP-9i) blocked the MMP-9 expression, and TGF-β1 gene expression in normal and diabetic GF at 24 h. The col1a1 gene expression was inhibited by MMP-9i only in normal GF but not in diabetic. TGF-β R1 was increased in normal and diabetic GF with PD, but MMP-9i decreased this expression only in diabetic GF. TGF-β inhibitor (SB431542) and Dexa abrogated MMP-9, TGF-β1 and col1a1 expression in normal and diabetic GF with PD at 24 h. TGF-β R1 was also inhibited in normal and diabetic GF with PD after 24 h of treatment with SB431542. Taken together, these findings suggests that diabetic individuals has increased synthesis of TGF-β and MMP-9 in GF during PD due to TGF-β R1 activation via Alk5 and presence of MMP-9. On the other hand, increased in the col1a1 expression is due to TGF-β R1 activation in normal and diabetic GF and presence of MMP-9 in normal GF.
In presence of Diabetes Mellitus, periodontal disease (PD) can accentuate complication appearance and increase prevalence. The aim of this study was to evaluate whether Transforming Growth factor-β 1 (TGF-β1) and Matrix Metaloproteinase-9 (MMP-9) are modulating the extracellular matrix components in gingival fibroblasts (GF) from diabetic mice (D) with PD. 24 animals were divided in 4 groups then they were treated with streptozotocin to diabetes induction and DP was inducted through a ligature with silk thread. After euthanasia and gingiva harvest, mice GF were cultured. MMP-9, TGF- β1, and type 1 Collagen (col1a1) mRNA expression and protein production were evaluated. They were also treated with MMP-9 and TGF-β inhibitors, and dexamethasone (Dexa) for 24h. Normal and diabetic GF from PD-induced mice had increased MMP-9 and TGF-β1 expression at 6 and 24 h decreasing at 48 h. Col1a1 gene expression was decreased in normal GF with PD at 6, 24 and 48 h. In diabetic GF col1a1 expression was inhibited at 6, 24 and 48 h. MMP-9 inhibitor (MMP-9i) blocked the MMP-9 expression, and TGF-β1 gene expression in normal and diabetic GF at 24 h. The col1a1 gene expression was inhibited by MMP-9i only in normal GF but not in diabetic. TGF-β R1 was increased in normal and diabetic GF with PD, but MMP-9i decreased this expression only in diabetic GF. TGF-β inhibitor (SB431542) and Dexa abrogated MMP-9, TGF-β1 and col1a1 expression in normal and diabetic GF with PD at 24 h. TGF-β R1 was also inhibited in normal and diabetic GF with PD after 24 h of treatment with SB431542. Taken together, these findings suggests that diabetic individuals has increased synthesis of TGF-β and MMP-9 in GF during PD due to TGF-β R1 activation via Alk5 and presence of MMP-9. On the other hand, increased in the col1a1 expression is due to TGF-β R1 activation in normal and diabetic GF and presence of MMP-9 in normal GF.
Descrição
Palavras-chave
Doença periodontal, Fibroblastos, Periodontal disease, Fibroblasts, Diabetes mellitus